TL;DR — Niacin (nicotinic acid) is the flush-inducing B3 form with the strongest human lipid-modifying evidence of any OTC supplement — raises HDL 15–35%, lowers LDL 5–25%, lowers Lp(a) 20–30% (Coronary Drug Project niacin arm, PMID 2044644). BUT: the AIM-HIGH and HPS2-THRIVE trials showed niacin + statin did NOT reduce cardiovascular events despite improving lipid panel, and added serious adverse events. Also a NAD+ precursor. Standard OTC dose 500–2,000 mg/day; the flush and hepatotoxicity issues make this a pharmaceutical-grade decision, not a casual supplement.
What niacin does (and why it matters)
Niacin (nicotinic acid) is the vitamin form that distinguishes itself from nicotinamide (also B3) by having direct pharmacological effects independent of NAD+A molecule every cell needs for energy production, DNA repair, and activating longevity genes (sirtuins). Full glossary → metabolism: - Lipid modification via HM74A / GPR109A receptor on adipocytes — inhibits lipolysis, reduces FFA delivery to liver → reduced VLDL secretion → cascade of lipid improvements - Flush — same GPR109A on Langerhans cells → prostaglandin D2 release → cutaneous vasodilation - NAD+ precursor — via the Preiss-Handler pathway, contributes to cellular NAD+ pool
The lipid effects are the pharmacological reason niacin was used for decades. The recent negative outcome trials (AIM-HIGH 2011; HPS2-THRIVE 2014) shook confidence but didn't erase mechanism.
Primary hallmarks targeted: Altered intercellular communication (lipid signaling) · Genomic instability (NAD+/PARP) · Deregulated nutrient sensing
Coronary Drug Project (CDP) niacin arm (Berge & Canner 1991, PMID 2044644) — 3,908 male MI survivors (1,119 niacin vs. 2,789 placebo) — niacin 3 g/day for 6 years reduced non-fatal MI recurrence and, in 15-year follow-up (Canner 1986), reduced all-cause mortality by 11% (PMID 3782631). AIM-HIGH (Boden 2011, PMID 22085343) — 3,414 patients on statin + niacin ER vs statin alone — no reduction in CV events; excess bleeding + infection. HPS2-THRIVE (2014, PMID 25014686) — 25,673 patients on statin ± niacin/laropiprant — negative for CV events; 4× serious adverse events.
Mechanism
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| GPR109A → adipocyte | ↓ Lipolysis → ↓ FFA delivery → ↓ VLDL synthesis → ↓ LDL, ↓ TG | Communication |
| HDL raising | ↓ CETP; ↑ ApoA-I stability | Communication |
| Lp(a) lowering | Mechanism uncertain; niacin uniquely effective (~20–30% reduction) | Communication |
| NAD+ precursor | Preiss-Handler pathway → NAD+ | Genomic instability |
| Flush | GPR109A on Langerhans → COX-1 → PGD2 → vasodilation | — |
The cognitive dissonance of niacin: it dramatically improves the lipid panel, but the AIM-HIGH/HPS2-THRIVE trials failed to translate that into cardiovascular event reduction when added on top of statin. This is an important lesson in surrogate endpoint fallacy — improving a lab number ≠ improving outcomes.
When niacin is worth considering
Niacin is worth thought only in narrow situations:
- Statin-intolerant patient needing LDL reduction (physician-supervised)
- Elevated Lp(a) — niacin is one of very few interventions that lower it (~20–30%)
- As NAD+ precursor alternative to NMN/NR at much lower cost (niacin at 100–500 mg)
- Familial dyslipidemia not adequately controlled by first-line therapy
Skip or defer for most people — the negative outcome trials, side-effect burden, and lack of clear healthy-person benefit make this a pharmacy-grade decision, not a routine supplement.
Evidence summary
| Study | Design | N | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Berge & Canner 1991 (PMID 2044644) | RCT (post-MI), CDP niacin arm | 3,908 | 6 yr | ↓ Non-fatal MI recurrence | A |
| Canner 1986 (PMID 3782631) | 15-yr CDP follow-up | 8,341 | 15 yr | ↓ All-cause mortality 11% | A |
| AIM-HIGH 2011 (PMID 22085343) | RCT (statin + niacin) | 3,414 | 3 yr | No benefit; excess AE | A |
| HPS2-THRIVE 2014 (PMID 25014686) | RCT (statin + niacin/laropiprant) | 25,673 | 4 yr | No benefit; 4× serious AE | A |
← Swipe for more columns →
Consensus: Tier A for lipid biomarker modification (uncontroversial). Tier B for hard cardiovascular outcomes when used alone (CDP was the era before statins). Tier A NEGATIVE for adding to statin therapy (AIM-HIGH, HPS2-THRIVE).
Where niacin disappoints
- AIM-HIGH and HPS2-THRIVE are Tier A NEGATIVE. On top of statin therapy, niacin adds harm, not benefit. - The flush is significant and non-negligible for daily quality of life. Aspirin 325 mg 30 min before dose reduces flush; extended-release forms reduce flush but increase hepatotoxicity risk. - Hepatotoxicity is real — mostly with sustained-release / no-flush products at doses >1,000 mg/day. Check LFTs at 3 months. - Glucose intolerance — niacin raises blood glucose by ~5–10 mg/dL; caution in prediabetes. - Uric acid — niacin raises uric acid; contraindicated in gout.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Lp(a) lowering / lipid (Rx-adjacent) | 1,000–2,000 mg/day IR divided BID | Physician-supervised |
| NAD+ precursor use | 100–500 mg/day | Much lower than lipid dose |
| Form | Immediate-release (flush + safe) or Niaspan ER (Rx) | Avoid OTC "no-flush" (inositol hexanicotinate) — different molecule |
| Titration | Start 100 mg BID; increase 100 mg weekly to target | Reduces initial flush |
| Timing | With food + aspirin 325 mg 30 min prior | Blunts flush |
Monitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Full lipid panel (Lp(a), HDL, LDL) | Target-directed | Baseline + 3 mo | Reassess whether benefit worth AE burden |
| LFTs (ALT, AST) | Normal | Baseline + 3 mo + annually | Discontinue if >3× ULN |
| Fasting glucose / HbA1c | Stable | 3 months | Adjust if worsening |
| Uric acid | < 6.0 mg/dL | 6 months | Discontinue if gout flare |
← Swipe for more columns →
Safety, red flags, and contraindications
- Flush is universal at IR doses ≥100 mg; tolerance builds over weeks.
- Hepatotoxicity — sustained-release forms carry higher risk.
- Glucose intolerance — modest but real.
Do not self-start without clearance
- Active liver disease — contraindicated.
- Gout — worsens uric acid.
- Type 1 or brittle T2D — glucose destabilization.
- On chronic statin — added risk without proven benefit per AIM-HIGH/HPS2-THRIVE.
- Peptic ulcer disease — can reactivate.
- Pregnancy — insufficient safety data at pharmacologic doses.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Aspirin (as flush blunter) | 325 mg 30 min pre-dose reduces flush 60% | Niacin protocol |
| Berberine | Complementary lipid mechanisms (berberine ↓ LDL, niacin ↑ HDL) | Metabolic stack |
| NMN / NR (NAD precursors) | Alternative NAD-raising strategy without lipid effects | NAD stack |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Statin (added on top) | Per AIM-HIGH / HPS2-THRIVE: no benefit, added harm | Discuss with lipid specialist |
| No-flush inositol hexanicotinate | Different molecule; doesn't produce niacin's effects | Use nicotinic acid IR |
| Alcohol (concurrent use) | Additive hepatotoxicity + flush | Time apart / reduce alcohol |
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.